EP1446007A4 - Methods and compositions for targeting underglycosylated proteins across the blood brain barrier - Google Patents
Methods and compositions for targeting underglycosylated proteins across the blood brain barrierInfo
- Publication number
- EP1446007A4 EP1446007A4 EP02801739A EP02801739A EP1446007A4 EP 1446007 A4 EP1446007 A4 EP 1446007A4 EP 02801739 A EP02801739 A EP 02801739A EP 02801739 A EP02801739 A EP 02801739A EP 1446007 A4 EP1446007 A4 EP 1446007A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- targeting
- compositions
- methods
- brain barrier
- blood brain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000008499 blood brain barrier function Effects 0.000 title 1
- 210000001218 blood-brain barrier Anatomy 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US136639 | 1993-10-13 | ||
| US32965001P | 2001-10-16 | 2001-10-16 | |
| US329650P | 2001-10-16 | ||
| US10/136,841 US7396811B2 (en) | 2001-04-30 | 2002-04-30 | Subcellular targeting of therapeutic proteins |
| US10/136,639 US20030072761A1 (en) | 2001-10-16 | 2002-04-30 | Methods and compositions for targeting proteins across the blood brain barrier |
| US136841 | 2002-04-30 | ||
| US38445202P | 2002-05-29 | 2002-05-29 | |
| US384452P | 2002-05-29 | ||
| US38601902P | 2002-06-05 | 2002-06-05 | |
| US386019P | 2002-06-05 | ||
| US40881602P | 2002-09-06 | 2002-09-06 | |
| US408816P | 2002-09-06 | ||
| PCT/US2002/032968 WO2003032727A1 (en) | 2001-10-16 | 2002-10-16 | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1446007A1 EP1446007A1 (en) | 2004-08-18 |
| EP1446007A4 true EP1446007A4 (en) | 2005-12-07 |
Family
ID=27558195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP02801739A Withdrawn EP1446007A4 (en) | 2001-10-16 | 2002-10-16 | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1446007A4 (en) |
| JP (2) | JP2005506340A (en) |
| AU (3) | AU2002362930A2 (en) |
| CA (1) | CA2463473A1 (en) |
| IL (1) | IL161352A0 (en) |
| WO (2) | WO2003032913A2 (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2300439T3 (en) | 2001-04-30 | 2008-06-16 | Zystor Therapeutics , Inc. | SUBCELLULAR RECOGNITION OF THERAPEUTIC PROTEINS. |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| WO2003102583A1 (en) * | 2002-05-29 | 2003-12-11 | Symbiontics, Inc. | Targeted therapeutic proteins |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| EP1446007A4 (en) * | 2001-10-16 | 2005-12-07 | Zystor Therapeutics Inc | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| CA2553955C (en) * | 2004-02-10 | 2012-08-28 | Zystor Therapeutics, Inc. | Acid alpha-glucosidase and fragments thereof |
| EP2182980A4 (en) | 2007-07-27 | 2012-04-18 | Armagen Technologies Inc | Methods and compositions for increasing alpha-iduronidase activity in the cns |
| PT2234600E (en) * | 2007-12-21 | 2014-09-25 | Hoffmann La Roche | Antibody formulation |
| EP3187508A1 (en) | 2008-05-07 | 2017-07-05 | BioMarin Pharmaceutical Inc. | Lysosomal targeting peptides and uses thereof |
| EP2475376B1 (en) | 2009-06-17 | 2016-03-30 | BioMarin Pharmaceutical Inc. | Formulations for lysosomal enzymes |
| EP3533467B1 (en) | 2009-10-09 | 2023-07-26 | Armagen, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
| ES2643015T3 (en) * | 2010-06-25 | 2017-11-21 | Shire Human Genetic Therapies, Inc. | Treatment of Sanfilippo Syndrome Type B |
| IL291554B2 (en) | 2010-06-25 | 2024-02-01 | Shire Human Genetic Therapies | Cns delivery of therapeutic agents |
| NZ702808A (en) | 2010-06-25 | 2016-08-26 | Shire Human Genetic Therapies | Methods and compositions for cns delivery of iduronate-2-sulfatase |
| BR112012033197A2 (en) | 2010-06-25 | 2017-06-06 | Shire Human Genetic Therapies | methods and compositions for releasing heparan n-sulfatase cns. |
| JP6045493B2 (en) | 2010-06-25 | 2016-12-14 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | Methods and compositions for CNS delivery of arylsulfatase A |
| DK3103469T3 (en) | 2010-06-25 | 2021-02-22 | Shire Human Genetic Therapies | Indgivelse af terapeutiske midler til centralnervesystemet |
| RU2014126484A (en) * | 2011-12-01 | 2016-02-10 | Ангиочем Инк. | AIMED COMPOUNDS OF LYSOSOMAL ENZYMES |
| WO2013096899A2 (en) | 2011-12-23 | 2013-06-27 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| US9687561B2 (en) | 2012-08-14 | 2017-06-27 | Angiochem Inc. | Peptide-dendrimer conjugates and uses thereof |
| ES2679374T3 (en) | 2012-11-27 | 2018-08-24 | Biomarin Pharmaceutical Inc. | Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof |
| EP3686217A1 (en) * | 2013-03-15 | 2020-07-29 | GlaxoSmithKline Intellectual Property (No.2) Limited | Low concentration antibody formulations |
| BR112016022333A2 (en) | 2014-04-01 | 2017-08-15 | Swedish Orphan Biovitrum Ab Publ | MODIFIED SULFAMIDASE AND PRODUCTION THEREOF |
| ES2826827T3 (en) | 2015-06-15 | 2021-05-19 | Angiochem Inc | Methods for the treatment of leptomeningeal carcinomatosis |
| EP3419651B1 (en) | 2016-02-24 | 2023-10-25 | BioMarin Pharmaceutical Inc. | Improved naglu fusion protein formulation |
| KR20210005154A (en) | 2018-04-30 | 2021-01-13 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Gene therapy constructs and methods of use |
| EA202190999A1 (en) | 2018-10-10 | 2021-10-15 | Амикус Терапьютикс, Инк. | COMPOSITIONS BASED ON POLYPEPTIDES STABILIZED WITH DISULPHIDE BONDING AND METHODS OF APPLICATION |
| US20220002688A1 (en) | 2018-12-20 | 2022-01-06 | Armagen, Inc. | Purification of iduronate-2-sulfatase immunoglobulin fusion protein |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991004014A1 (en) * | 1989-09-21 | 1991-04-04 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
| WO1995002421A1 (en) * | 1993-07-16 | 1995-01-26 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
| WO2002087510A2 (en) * | 2001-04-30 | 2002-11-07 | Symbiontics, Inc. | Subcellular targeting of therapeutic proteins |
| WO2003032913A2 (en) * | 2001-10-16 | 2003-04-24 | Symbiontics Inc. | Methods and compositions for targeting proteins across the blood brain barrier |
| WO2003102583A1 (en) * | 2002-05-29 | 2003-12-11 | Symbiontics, Inc. | Targeted therapeutic proteins |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US6472140B1 (en) * | 1997-09-05 | 2002-10-29 | The General Hospital Corporation | α-2- macroglobulin therapies and drug screening methods for Alzheimer's disease. |
-
2002
- 2002-10-16 EP EP02801739A patent/EP1446007A4/en not_active Withdrawn
- 2002-10-16 IL IL16135202A patent/IL161352A0/en unknown
- 2002-10-16 AU AU2002362930A patent/AU2002362930A2/en not_active Abandoned
- 2002-10-16 WO PCT/US2002/032996 patent/WO2003032913A2/en not_active Application Discontinuation
- 2002-10-16 AU AU2002347910A patent/AU2002347910A1/en not_active Abandoned
- 2002-10-16 CA CA002463473A patent/CA2463473A1/en not_active Abandoned
- 2002-10-16 WO PCT/US2002/032968 patent/WO2003032727A1/en active Application Filing
- 2002-10-16 JP JP2003535542A patent/JP2005506340A/en active Pending
-
2009
- 2009-06-16 JP JP2009143436A patent/JP2009203241A/en active Pending
-
2010
- 2010-08-25 AU AU2010214643A patent/AU2010214643A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991004014A1 (en) * | 1989-09-21 | 1991-04-04 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
| WO1995002421A1 (en) * | 1993-07-16 | 1995-01-26 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
| WO2002087510A2 (en) * | 2001-04-30 | 2002-11-07 | Symbiontics, Inc. | Subcellular targeting of therapeutic proteins |
| WO2003032913A2 (en) * | 2001-10-16 | 2003-04-24 | Symbiontics Inc. | Methods and compositions for targeting proteins across the blood brain barrier |
| WO2003102583A1 (en) * | 2002-05-29 | 2003-12-11 | Symbiontics, Inc. | Targeted therapeutic proteins |
Non-Patent Citations (2)
| Title |
|---|
| DUFFY K R ET AL: "Human blood-brain barrier insulin-like growth factor receptor", METABOLISM, CLINICAL AND EXPERIMENTAL, W.B. SAUNDERS CO., PHILADELPHIA, PA, US, vol. 37, no. 2, 1 February 1988 (1988-02-01), pages 136 - 140, XP026359542, ISSN: 0026-0495, [retrieved on 19880201] * |
| See also references of WO03032727A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1446007A1 (en) | 2004-08-18 |
| WO2003032727A1 (en) | 2003-04-24 |
| AU2002362930A2 (en) | 2003-04-28 |
| AU2010214643A1 (en) | 2010-09-16 |
| WO2003032913A2 (en) | 2003-04-24 |
| AU2002347910A1 (en) | 2003-04-28 |
| WO2003032913A3 (en) | 2004-08-12 |
| JP2009203241A (en) | 2009-09-10 |
| WO2003032913A9 (en) | 2004-04-29 |
| IL161352A0 (en) | 2004-09-27 |
| CA2463473A1 (en) | 2003-04-24 |
| JP2005506340A (en) | 2005-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL161352A0 (en) | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier | |
| PT1757606E (en) | Xanthinderivatives for use as medical agents and the preparation thereof | |
| IL160001A0 (en) | Peptide based multimeric targeted contrast agents and methods for the preparation thereof | |
| GB0101990D0 (en) | Surgical system | |
| HK1068812A1 (en) | Drug preparations | |
| EP1391209A4 (en) | Protein formulations | |
| GB0104534D0 (en) | Pharmaceutical combination | |
| IL160998A0 (en) | Human tissue factor antibodies | |
| GB0218205D0 (en) | Human ZZAP1 protein | |
| GB0124523D0 (en) | Pharmaceutical combination | |
| GB0118383D0 (en) | Therapeutic methods | |
| GB0129270D0 (en) | Pharmaceutical combination | |
| GB0129397D0 (en) | Pharmaceutical combination | |
| IL158587A0 (en) | Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof | |
| GB0209356D0 (en) | Medical facemask | |
| GB0129395D0 (en) | Pharmaceutical combination | |
| AU2002365148A8 (en) | Human ras interacting protein | |
| GB0410147D0 (en) | Human angiomotin-like protein 1 | |
| GB0128138D0 (en) | Pharmaceutical use | |
| GB0122061D0 (en) | Vision therapy | |
| IL145821A0 (en) | Oral-nasal cannula | |
| GB0201819D0 (en) | Human posh-like protein 1 | |
| GB0201681D0 (en) | Human ralgds-like protein 3 | |
| GB0128865D0 (en) | Diathermy forceps connection means | |
| IL144389A0 (en) | Medical database |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20040514 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ZYSTOR THERAPEUTICS , INC. |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20051024 |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SLY, WILIAN, S. Inventor name: LEBOWITZ, JONATHAN, H. |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SLY, WILIAN, S. Inventor name: DR JONATHAN LEBOWITZ |
|
| 17Q | First examination report despatched |
Effective date: 20060322 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BIOMARIN PHARMACEUTICAL INC. |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20120112 |